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Abstract
Here we evaluate the current status of clinical research on regional hyperthermia (RHT) in combination with
chemotherapy or radiation therapy in paediatric oncology.
Data were identified in searches of MEDLINE, Current Contents, PubMed, and references from relevant articles using
medical subject headings including hyperthermia, cancer, paediatric oncology, children, radiation therapy and
chemotherapy. Currently, only two RHT centres exist in Europe which treat children. Clinical RHT research in
paediatric oncology has as yet been limited to children with sarcomas and germ cell tumours that respond poorly
to or recur after chemotherapy. RHT is a safe and effective treatment delivering local thermic effects, which may
also stimulate immunological processes via heat-shock protein reactions. RHT is used chiefly in children and
adolescents with sarcomas or germ cell tumours located in the abdomino-pelvic region, chest wall or extremities to
improve operability or render the tumour operable. It could potentially be combined with radiation therapy in a
post-operative R1 setting where more radical surgery is not possible or combined with chemotherapy instead of
radiation therapy in cases where the necessary radiation dose is impossible to achieve or would have mutilating
consequences. RHT might also be an option for chemotherapy intensification in the neoadjuvant first-line treatment
setting for children and adolescents, as was recently reflected in the promising long-term outcome data in adults
with high-risk soft tissue sarcomas (EORTC 62961/ESHO trial).
The limited data available indicate that combining RHT with chemotherapy is a promising option to treat germ cell
tumours and, potentially, sarcomas. RHT may also be beneficial in first-line therapy in children, adolescents and
young adults. The research should focus on optimising necessary technical demands and then initiate several
clinical trials incorporating RHT into interdisciplinary treatment of children, adolescents and young adults that
include translational research components exploring potential immunological mechanisms of action.
Introduction – current situation
In contrast to adult oncology, tumours of mesenchymal
and neuroectodermal origin predominate in paediatric
oncology. While sarcomas occur in all age groups, they are
relatively more common in children and adolescents than
later in life. In the course of the years, co-operative treat-
ment optimisation studies have led to marked optimisation
of systemic polychemotherapy, for example for the group
of soft tissue sarcomas [1]. The possibilities for optimisation
of these conventional chemotherapy protocols appears to
have reached a level where only new mechanisms of action
and innovative strategies can produce further improve-
ments with clinical relevance. Epigenetic and immuno-
logical treatment approaches can be expected to play an
increasing role in the coming years, but these are still at the
stage of clinical development. Successful treatment for sar-
comas incorporates both effective systemic neo-/adjuvant
therapy and local control even when the tumour has metas-
tasised to improve overall survival (OS) [2]. Despite a
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frequently unfavourable location of the primary tumour,
the aim is always to permit R0 resection with as little func-
tional loss as possible. Here there have also been marked
improvements in both surgical and radiation therapy strat-
egies in the past years and new techniques have been intro-
duced. In spite of modern radiation therapy techniques
such as proton therapy, stereotactic radiation therapy or ra-
diosurgery, and experimental procedures such as isolated
limb perfusion chemotherapy, effective local therapy can
present a success-limiting problem in the individual case.
But even in the case of effective local therapy, acute and
long-term side effects of surgery and/or radiation therapy
can present a relevant problem.
Regional hyperthermia (RHT), offers an interesting
approach that acts synergistically with chemotherapy and
radiation therapy without producing disproportionate add-
itional side effects, provided that current quality assurance
guidelines for treatment planning and application are
followed [3–5]. The rationale is a synergistic thermic che-
mosensitation through the use of alkylating substances such
as cyclophosphamide or ifosfamide, platinum derivatives or
anthracyclines [6] as established in the Hyper-PEI protocol
and the german study group for malignant germ cell
tumors (MAKEI) [7]. RHT in combination with chemo-
therapy is the best investigated thermotherapy procedure in
both adult and paediatric oncology to date [8, 9]. This re-
view aims to summarize the current knowledge on RHT in
the treatment of paediatric, adolescent and young adult pa-
tients and provide some discussion points and future
perspectives.
Methods
Data for this paper were identified by searches of MED-
LINE, Current Contents, PubMed, and references from
relevant articles using medical subject headings includ-
ing hyperthermia, cancer, paediatric oncology, children,
radiotherapy and chemotherapy.
Results
Regional hyperthermia with chemotherapy
The search strategy identified six reports on prospective
clinical trials without control groups (Table 1). The data
on RHT or hyperthermic chemotherapy in children and
adolescents are currently limited, and only two active
German hyperthermia centres treating paediatric pa-
tients were identified, the Heinrich Heine University
Hospital Düsseldorf and the Charité-Universitätsmedizin
Berlin. The study by Romanowski et al. was the first which
combined RHTand systemic chemotherapy (ICE: etoposide
4 × 150 mg/m2 and ifosfamide 4 × 2000 mg/m2 or carbo-
platin 4 x 150 mg/m2) in 34 intensively pretreated children
and adolescents with prognostically unfavourable tumour
diseases [10]. Romanowski et al. reported that 20 % of
patients experienced a complete remission and 7 patients
remained alive up to 64 months after the combined treat-
ment. A second pilot trial treated 9 patients with locoregio-
nal recurrences of abdominal germ cell tumors with PEI
chemotherapy (PEI: cisplatin 40 mg/m2 on days 1 and 4,
etoposide 100 mg/m2 on days 1 to 4 and ifosfamide
2000 mg/m2 on days 1 to 4) in combination with RHT but
with or without radiation treatment. Event-free survival
(EFS) in these 9 patients (EFS 0.41 ± 0.33) who received
RHT was significantly better than in a matched cohort
(EFS 0.16 ± 0.25) who did not receive RHT, supporting the
idea that RHT can have a relevant impact on local tumor
control and patient EFS [11]. A further report on 10 pa-
tients from a phase I/II trial in children and adolescents
with recurrent or refractory germ cell tumours treated at
the University Hospital Düsseldorf with RHT combined
with platinum-based PEI chemotherapy demonstrated
feasibility and efficacy with objective tumour response rates
up to 70 % [12]. Of these 10 patients, 2 responded partially
and 5 had a complete response. Schneider et al. reported
on a prospective trial without a control group for patients
with relapsed malignant sacrococcygeal germ cell tumours
who received cisplatin-based first-line polychemotherapy
and tumour resection according to the MAKEI trial [7]. In
this trial, 22 patients with first relapses, 14 with second re-
lapses and 7 with later relapses were treated by surgery and
adjuvant platinum chemotherapy. Pre-operative chemo-
therapy was administered together with RHT with the aim
to improve operability in a subgroup of 8 poor responders
or patients with locally advanced tumours. Although the
small number of patients limits the informative value, the
effect of RHT in this study was better when applied early
resulting in 4 complete remissions after first or second
relapses.
The group of Wessalowski at the University Hospital
Düsseldorf published two further trials. The first trial in-
cluded 39 patients, 24 with extracranial non-testicular
germ cell tumours and 15 with soft tissue sarcomas or
chondrosarcomas, of which 29 tumours were locoregional
relapses and 10 were unresectable following pre-operative
chemotherapy. Of these 39 patients treated with RHT ac-
cording to the Hyper-PEI protocol, 20 achieved complete
remission and 10 achieved partial remission. A consecu-
tive surgical tumour resection was possible in 28 of these
patients, while 13 patients required additional radiother-
apy. After 5 years of follow-up, EFS was 0.39 ± 0.11 (20/39
patients) and OS was 0.52 ± 0.11 (25/39 patients). This
interdisciplinary treatment of RHT with chemotherapy
enabled a successful local therapy leading to a sustained
remission in most patients with high risk for tumour
recurrence [9]. Wessalowski et al. also used RHT in com-
bination with chemotherapy for salvage treatment in 44
children and adolescents with refractory or recurrent non-
testicular malignant germ-cell tumours [8]. Sufficient data
could only be obtained for 35 of the 44 patients, of which
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Table 1 Design of clinical studies employing regional hyperthermia with chemotherapy
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30 (86 %) had an objective response to the combination of
RHT and PEI chemotherapy. PEI-regional deep hyperther-
mia utilised 40 mg/m(2) cisplatin delivered intravenously
on days 1 and 4, 100 mg/m(2) etoposide delivered intraven-
ously on days 1–4 and 1800 mg/m(2) ifosfamide delivered
intravenously on days 1–4. One hour of RHT (41–43 °C)
on days 1 and 4 was applied simultaneously with chemo-
therapy. Wessalowski et al. showed that 16 of these patients
achieved complete remission and 14 achieved partial remis-
sion. The 5-year EFS and OS was 62 and 72 %, respectively,
and toxicity was tolerable with only reports of WHO grade
3–4 neutropenia and thrombocytopenia occurring after all
chemotherapy cycles. This was the first data showing that
RHT combined with PEI could improve the long-term out-
come of children and adolescents with refractory or recur-
rent malignant non-testicular germ-cell tumours.
Notably, more recent data from adult patients with
high-risk soft tissue sarcomas treated within the EORTC
62961/ESHO randomised trial showed that peri-operative
chemotherapy combined with RHT significantly improved
either disease-free survival or OS [13, 14], supporting
combined RHT and chemotherapy as a reference therapy
for adults with high-risk soft tissue sarcomas. These re-
sults indicated that RHT not only improved the local
chemotherapy effect, but that it may also have stimulated
immunological processes which could permit longer-term
tumour control [15, 16]. Whether this approach would
also be successful in first-line treatment of paediatric pa-
tients with sarcomas has yet to be demonstrated.
Further hyperthermia procedures
There are no data from trials combining RHTand radiation
therapy (thermoradiotherapy) in paediatric patients, how-
ever, the limited experience reported in case reports on
paediatric patients support that application would probably
have similar synergistic effects as in adults. Results from the
combination of radiation therapy and hyperthermia for lo-
cally advanced cervical cancer in adult patients are worth
mentioning in this context. The Dutch Deep Hyperthermia
Trial not only showed an 83 % local control rate for com-
bined radiation therapy and RHT versus 57 % for radiation
therapy alone, but also a 3-year OS of 51 % for radiation
therapy combined with RHT, compared to 27 % with radi-
ation therapy alone [17]. The 12-year OS was still almost
twice as high after combined radiation therapy and RHT
(37 %), versus 20 % with radiation therapy alone [18].
There is currently no data available for whether the
post-operative use of RHT together with radiation
therapy in on paediatric patients is beneficial com-
pared to radiation therapy alone. It remains unclear
whether radiation therapy could be omitted under cer-
tain circumstances and the R1 area treated instead
with a combination of RHT and chemotherapy. Future
prospective trials are necessary to evaluate the out-
come and toxicities of these approaches [18].
Whole-body hyperthermia
Less is known regarding whole-body hyperthermia in chil-
dren, a procedure aiming to establish a steady state with
maximal temperatures of 42 °C that is maintained for 1 h.
Such a procedure can be achieved only with deep analgesia
and sedation or general anaesthesia using radiant systems
which have been reviewed before [19]. Therefore, the ef-
forts needed (including intensive medical care) are much
greater than for locoregional methods. Apart from a few in-
dividual cases [19–21], there is practically no experience
with whole-body hyperthermia in children. There is also no
solid data available on the use of whole-body hyperthermia
in adults [19].
Special indications such as desmoid tumours/aggressive
fibromatosis
There were a number of positive reports on RHT and its
combination with radiation therapy in patients with des-
moid tumours. To date, some limited data for individual
cases in paediatric patients support that it could be an
appropriate second-line option for complex refractory
situations [22–25].
Discussion
Technical solutions for RHT in children
In paediatrics, body weights range from under 5 kg to
adult weight. This means that the technical require-
ments for the widely differing weights and, thus, widely
Table 2 Available applicators for use in children and adolescents
Available applicators with dimensions, treatable craniocaudal tumour length and permitted maximal lateral and dorsoventral dimensions of the
patient
Sigma 30 Sigma 40 Sigma Eye
Applicator length (bolus) 25 40 50
Applicator internal
diameter (bolus)




Maximal lateral (x) and dorsoventral (y)
patient dimensions (pelvis/abdomen)
x ≤ 19 cm
y ≤ 19 cm
19 cm < x ≤ 34 cm
19 cm < y ≤ 34 cm
19 cm < x ≤ 44 cm
19 cm < y ≤ 29 cm
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differing body and organ dimensions are complex. In
addition to the special body dimensions in children,
their stress tolerance for RHT is considerably lower and
decreases with the age of the child. Experience has
shown that from the beginning of puberty children are
able to tolerate an RHT session without deep sedation or
general anaesthesia. Table 2 shows the dimensions of the
commercially available applicators that can be used in
children together with the respective patient and tumour
dimensions treatable. These technical solutions can gen-
erate intratumoral temperatures of up to 43 °C, which
correspond to the successful treatment protocols in chil-
dren and adults.
Feasibility in children and side effects
The same body regions accessible in adults are accessible
in children, with bones, lungs and the CNS being diffi-
cult to reach in all patients regardless of age. Children
do have some special needs during RHT, however, and
require more analgesics and need them applied earlier in
combination with deep sedation or anaesthesia during
RHT application [11, 12]. There are no concerns against
RHT in combination with deep sedations or narcosis, al-
though the temperature around certain organs at risk,
including the skin, must be monitored carefully because
of the missing perception of pain. Side effects of RHT
are temperature-associated and generally rare events, as
children are considerably more tolerant to temperature
elevation than adults. Genuine burns are very rare. The
greater risk is associated with the additional chemother-
apy or radiation therapy and their associated toxicities.
RHT offers a possible method to intensify local therapy
without significant additional toxicity.
Conclusion
RHT can be considered for children with solid tumours,
particularly germ cell tumours and soft-tissue sarcomas,
and in cases of refractory tumours, recurrences or situa-
tions where standard treatments cannot be used. RHT
should be applied early in the relapse situation. An import-
ant conclusion from the analysed trials is the observation
that patients with recurrent germ cell tumours can be
cured by RHT, even in cases where cispatin resistence arose
during earlier therapy. RHT could be considered in individ-
ual cases with complex refractory situations for rare tu-
mours, such as desmoid tumours. Currently available data
from children [8, 12] and the more recent data from adults
with soft tissue sarcomas [14] indicate that RHT could be
an effective treatment option that should be further devel-
oped and investigated in children. Long-term immuno-
logical effects that potentially result from the heat-shock
reaction should be closely monitored in children receiving
RHT [26, 27], since clinical data to date suggest that the ef-
fects go beyond improved local control [14]. A prospective
treatment optimisation trial for RHT combined with
chemotherapy in the second-line treatment of sarcomas in
children, adolescents and young adults is in preparation at
the Charité – Universitätsmedizin Berlin.
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